BMT CTN 1902: Phase II Multicenter Trial of anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for Multiple Myeloma Patients with Sub-Optimal Response After Autologous Hematopoietic Cell Transplantation and Maintenance Lenalidomi
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
National Marrow Donor Program
Start Date
October 27, 2022
End Date
October 30, 2027
Administered By
Duke Cancer Institute
Awarded By
National Marrow Donor Program
Start Date
October 27, 2022
End Date
October 30, 2027